Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach

Genet Med. 2020 Aug;22(8):1320-1328. doi: 10.1038/s41436-020-0807-4. Epub 2020 May 5.

Abstract

Purpose: To present results from a large cohort of individuals receiving expanded carrier screening (CS) in the United States.

Methods: Single-gene disorder carrier status for 381,014 individuals was determined using next-generation sequencing (NGS) based CS for up to 274 genes. Detection rates were compared with literature-reported values derived from disease prevalence and carrier frequencies. Combined theoretical affected pregnancy rates for the 274 screened disorders were calculated.

Results: For Ashkenazi Jewish (AJ) diseases, 81.6% (4434/5435) of carriers identified did not report AJ ancestry. For cystic fibrosis, 44.0% (6260/14,229) of carriers identified had a variant not on the standard genotyping panel. Individuals at risk of being a silent spinal muscular atrophy carrier, not detectable by standard screening, comprised 1/39 (8763/344,407) individuals. For fragile X syndrome, compared with standard premutation screening, AGG interruption analysis modified risk in 83.2% (1128/1356) premutation carriers. Assuming random pairing across the study population, approximately 1/175 pregnancies would be affected by a disorder in the 274-gene screening panel.

Conclusion: Compared with standard screening, NGS-based CS provides additional information that may impact reproductive choices. Pan-ethnic CS leads to substantially increased identification of at-risk couples. These data support offering NGS-based CS to all reproductive-aged women.

Keywords: carrier frequencies; carrier screening; pan-ethnic screening; pathogenic variants; single-gene disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ethnicity
  • Female
  • Fragile X Syndrome* / diagnosis
  • Fragile X Syndrome* / epidemiology
  • Fragile X Syndrome* / genetics
  • Genetic Carrier Screening
  • Genetic Testing*
  • Heterozygote
  • Humans
  • United States / epidemiology